| pubmed-article:19468200 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19468200 | lifeskim:mentions | umls-concept:C0036203 | lld:lifeskim |
| pubmed-article:19468200 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:19468200 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:19468200 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:19468200 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:19468200 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:19468200 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19468200 | pubmed:dateCreated | 2009-8-12 | lld:pubmed |
| pubmed-article:19468200 | pubmed:abstractText | Cutaneous sarcoidosis may be a chronic disease with important morbidity requiring aggressive therapy. The efficacy of different anti-tumor necrosis factor alpha(anti-TNF-alpha) treatments in refractory cutaneous and systemic sarcoidosis has been reported previously. We report the first patient with chronic cutaneous sarcoidosis who responded to dose escalation of anti-TNF-alpha agents that have been ineffective at the standard dosage, illustrating that the optimal dosing regimen has still to be defined for this indication before considering difficult-to-treat patients as nonresponders. Our case report also illustrates that the fusion protein etanercept, even used at a high dosage, may be less effective for the treatment of cutaneous sarcoidosis than the monoclonal antibodies infliximab and adalimumab. | lld:pubmed |
| pubmed-article:19468200 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19468200 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19468200 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19468200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19468200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19468200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19468200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19468200 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19468200 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19468200 | pubmed:issn | 1421-9832 | lld:pubmed |
| pubmed-article:19468200 | pubmed:author | pubmed-author:BardaGG | lld:pubmed |
| pubmed-article:19468200 | pubmed:author | pubmed-author:LaffitteEE | lld:pubmed |
| pubmed-article:19468200 | pubmed:author | pubmed-author:SauratJ-HJH | lld:pubmed |
| pubmed-article:19468200 | pubmed:author | pubmed-author:ThielenA-MAM | lld:pubmed |
| pubmed-article:19468200 | pubmed:copyrightInfo | 2009 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:19468200 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19468200 | pubmed:volume | 219 | lld:pubmed |
| pubmed-article:19468200 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19468200 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19468200 | pubmed:pagination | 59-62 | lld:pubmed |
| pubmed-article:19468200 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:meshHeading | pubmed-meshheading:19468200... | lld:pubmed |
| pubmed-article:19468200 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19468200 | pubmed:articleTitle | Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. | lld:pubmed |
| pubmed-article:19468200 | pubmed:affiliation | Dermatology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland. anne-marie.thielen@hcuge.ch | lld:pubmed |
| pubmed-article:19468200 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19468200 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19468200 | lld:pubmed |
